Menu
Not yet recruiting NCT07705997

Prospective Cohort Study of Aging in Patients With Acute Myocardial Infarction

Observational Acute Myocardial Infarction (AMI)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Acute Myocardial Infarction (AMI). Basic parameters: from 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Single-Center, Prospective, Observational Registry Cohort Study to Investigate Aging-Related Biomarkers, Prognosis, and Risk Prediction in Patients With Acute Myocardial Infarction

Overview

This is a single-center, prospective, observational cohort study designed to investigate the association between aging-related characteristics and long-term outcomes in patients with acute myocardial infarction (AMI). Approximately 588 eligible participants will be consecutively enrolled and followed for at least 24 months. Clinical data, aging assessments, laboratory examinations, cardiac imaging, and blood samples will be collected to establish a clinical database and biobank. The study aims to identify aging-related prognostic biomarkers, develop a risk prediction model integrating clinical and aging-related indicators, and improve risk stratification and individualized management for patients with AMI.

Primary outcome measures

  • Major adverse cardiovascular events (MACE) [Time frame: Baseline through 24 months of follow-up]
Secondary outcome measures (6)
  • All-cause mortality [Time frame: Baseline through 24 months]
  • Cardiovascular mortality [Time frame: Baseline through 24 months]
  • Hospitalization for heart failure [Time frame: Baseline through 24 months]
  • Recurrent myocardial infarction [Time frame: Baseline through 24 months]
  • Aging-related serious adverse events [Time frame: Baseline through 24 months]
  • Prognostic performance of the aging-related risk prediction model [Time frame: At completion of the 24-month follow-up]

Eligibility criteria

Inclusion criteria

  • 1\. Age ≥ 60 years old and meet the above comprehensive aging assessment criteria (i.e., combined with at least one clinical phenotype of aging and abnormal blood aging markers on the basis of advanced age); 2. Acute myocardial infarction occurs for ≥ 3 months; 3. Meet the diagnostic criteria for AMI in accordance with the Fourth Edition General Definition of Myocardial Infarction; 4. The patient or their legal representative signs an informed consent form.

Exclusion criteria

  • 1\. Newly diagnosed acute myocardial infarction, angina pectoris, stroke or transient ischemic attack within the past 3 months; 2. Serious life-threatening diseases (such as advanced malignant tumors, end-stage kidney disease/liver disease, severe infections) with an estimated lifespan of less than 1 year; 3. Severe cognitive impairment, mental illness, inability to cooperate in completing follow-up, aging assessment, and related examinations; 4. Unable to complete assessment items such as grip strength, walking speed, and 6-minute walk test due to non cardiac reasons such as physical disabilities and severe bone and joint diseases; 5. Failed to sign the informed consent form.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • MingWei Wang — Hanzhou

Identifiers

NCT: NCT07705997 · 2026(E2)-KS- 098

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗